Pharmacyte Biotech Inc (OTCMKTS:PMCB) is one of the OTC traded stocks that has the potential to capture a small share of the market where the big companies like Celgene Corporation (NASDAQ:CELG) and Eli Lilly and Co(NYSE:LLY) dominates. The market where Pharmacyte can get an edge over the big companies is pancreatic cancer. It is an area where Eli and Celgene both contribute to the preferred therapy, a combination of gemcitabine and Abraxane. The drug Abraxane is developed by Celgene whereas gemcitabine is formulated by Eli.

The drug combination of gemcitabine and Abraxane is not essentially the most effective treatment option. However, as of now, it is only the treatment that is well tolerable. There is also a generic drug known as ifosfamide that may prove to be more effective. The concern is, the dose size needed for ifosfamide to become as effective treatment for pancreatic cancer results in adverse side effects following which it cannot get FDA’s approval. However, if the dose could be lowered to well-tolerated levels without compromising on efficacy, it can prove to be much more effective than present drug combination of gemcitabine and Abraxane. So, how can it be made possible? Well, the answer lies with Pharmacyte Biotech Inc (OTCMKTS:PMCB).

Most intravenous cancer drugs are simply injected in their final active form. However, they fail to reach the actual cancer affected part. Pharmacyte Biotech Inc (OTCMKTS:PMCB) encapsulating technology can prove to be beneficial here. The encapsulating of live cells produces a specific enzyme that turns a molecule into actual ifosfamide and positions those encapsulated cells close to the tumor.

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has developed a call capsule that is now in Phase II testing. In the initial testing process, the delivery of ifosfamide in the Pharmacyte’s designed way has enhanced the median survival duration from 28 to 44 weeks. Also, the count of one-year survivors in the trial increased to 36% from 18%. The company is taking all the measures it can to become a leading name in the biotech world.